When independent laboratories test peptide products sold for research use, the quantity on the label and the quantity in the vial rarely match exactly. The gap — whether positive or negative — is one of the most practically informative data points that test aggregators collect, and understanding what it typically means helps researchers interpret certificates of analysis (COAs) and batch reports more critically.
What "labeled vs. tested" quantity data shows
Contract analytical labs such as Janoshik conduct HPLC-based mass assays and publish quantitative purity and mass data alongside identity confirmation; aggregator platforms such as Finnrick and Peptigrity then index those results across many vendors and lots. When a product label reads "5 mg" and an HPLC-based mass assay returns 5.4 mg, that 8% surplus is logged as a positive overage. When the assay returns 4.3 mg, the 14% shortfall is a negative overage — commonly called underdosing.
Across publicly available test datasets, results cluster into three rough patterns: products that land within a narrow band of label claim (roughly ±5–10%), products that run meaningfully above label claim, and products that fall meaningfully below it. The distribution is not symmetric — the research community has noted that underdosing appears less frequently in products from suppliers who submit to routine third-party testing, though gaps still occur.
Overage as a manufacturing buffer
A modest positive overage is common in pharmaceutical and research-chemical manufacturing. Overage is built in to compensate for degradation over shelf life, minor losses during lyophilization or fill-and-finish, and the natural variance of analytical methods themselves. USP and comparable pharmacopoeial standards describe acceptable tolerances for active pharmaceutical ingredients, and many reference manufacturers — including firms such as Bachem and PolyPeptide Group that serve regulated markets — operate within defined overage windows as standard practice.
For research-grade peptides, a product testing at 105–115% of label claim is therefore not automatically a concern. It may reflect intentional buffer, lot-to-lot variability, or both. The more meaningful signal is whether overage is *consistent* across lots from the same source, which suggests controlled manufacturing, versus erratic, which may suggest inconsistent process control.
| Result vs. label | Common interpretation | Notes |
|---|---|---|
| +5% to +15% | Expected buffer / normal variance | Acceptable in most reference frameworks |
| +15% to +30% | Elevated overage | Worth noting; may indicate process variability |
| >+30% | High overage | Warrants scrutiny of assay method and source |
| -1% to -10% | Minor shortfall | Within some tolerance windows; context-dependent |
| -10% to -25% | Meaningful underdosing | Consistent red flag in aggregated data |
| <-25% | Severe underdosing | Strong signal of quality or integrity concern |
Underdosing as a red flag
While overage carries a plausible benign explanation, underdosing — receiving meaningfully less material than the label claims — has a narrower set of explanations, most of them unfavorable. Possible causes include inaccurate filling by the manufacturer, deliberate short-filling to reduce cost, degraded material that has lost mass over time (often correlated with failed purity results), or simple mislabeling. Aggregated test data published by platforms such as VialAudit and PeptideBenchmark shows that underdosing frequently co-occurs with purity failures, suggesting a shared root cause in manufacturing or storage conditions rather than isolated weighing error.
Researchers reviewing supplier test records are advised — by testing platforms and by community documentation and forum resources — to treat a single underdosed result with caution and a pattern of underdosed results across multiple lots as a meaningful quality signal. Vendor-supplied COAs, while useful, do not substitute for independent third-party testing because the testing lab is not beholden to the seller.
Reading test data in context
No single data point tells a complete story. A mass assay result should be read alongside purity (HPLC area %), identity confirmation (typically mass spectrometry), and lot consistency over time. Overage and underdosing figures published by independent aggregators represent a snapshot of what was tested at a specific time from a specific lot; they do not guarantee future lots will perform identically. Researchers sourcing peptides for in-vitro or in-vivo study should treat third-party quantity data as one input in a broader quality evaluation, not as a pass/fail verdict on a supplier.